Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof

A method for inhibiting ventricular dilatation, comprising an administration to a mammal of HGF protein or a salt thereof,

• wherein the mammal is a mammal with a polyglutamine aggregation-caused disease or a mammal with a gene responsible for a polyglutamine aggregation-caused disease having about 30 CAG repeats or more, and
• the HGF protein or salt thereof is administered into the striatum or the spinal parenchyma, or is intrathecally administered, and
• 10 μg to 50 mg of HGF protein is administered in a single dose.

A method for inhibiting neurodegeneration or cell death dependent on a gene product responsible for a polyglutamine aggregation-caused disease, comprising an administration to a mammal of HGF protein or a salt thereof,

• wherein the mammal is a mammal with a polyglutamine aggregation-caused disease or a mammal with a gene responsible for a polyglutamine aggregation-caused disease having about 30 CAG repeats or more, and
• the HGF protein or salt thereof is administered into the striatum or the spinal parenchyma, or is intrathecally administered, and
• 10 μg to 50 mg of HGF protein is administered in a single dose.

A method for inhibiting caspase-3 and/or caspase-1 activation in a neuron, comprising an administration to a mammal of HGF protein or a salt thereof,

• wherein the mammal is a mammal with a polyglutamine aggregation-caused disease or a mammal with a gene responsible for a polyglutamine aggregation-caused disease having about 30 CAG repeats or more, and
• the HGF protein or salt thereof is administered into the striatum or the spinal parenchyma, or is intrathecally administered, and
• 10 μg to 50 mg of HGF protein is administered in a single dose.

A method for inhibiting a processing of a gene product responsible for a polyglutamine aggregation-caused disease, comprising an administration to a mammal of HGF protein or a salt thereof,

• wherein the mammal is a mammal with a polyglutamine aggregation-caused disease or a mammal with a gene responsible for a polyglutamine aggregation-caused disease having about 30 CAG repeats or more, and
• the HGF protein or salt thereof is administered into the striatum or the spinal parenchyma, or is intrathecally administered, and
• 10 μg to 50 mg of HGF protein is administered in a single dose.